Bosch Healthcare Solutions (BHCS) has announced the launch of the world’s first fully automated PCR test for the detection of B. pertussis, B. parapertussis, and B. holmesii. This new test, called Vivalytic Bordetella, is specifically designed for near-patient testing and provides results in under an hour.
The Vivalytic test is a significant development in the fight against whooping cough, as it allows for the specific detection of all three pathogens responsible for the disease. This is crucial for targeted antibiotic treatment in the early stages of the infection and for controlling its spread.
According to Marc Meier, president of Bosch Healthcare Solutions, the Vivalytic Bordetella test is a response to the rising number of pertussis cases in Germany. The infection rates for pertussis have reached their highest levels in recent years, with a high hospitalization rate among newborns and the elderly.
The Vivalytic Bordetella test is now available for immediate order through distribution partners such as Randox Laboratories and R-Biopharm.
Prompt diagnosis is crucial for effective treatment of pertussis, as the disease can be life-threatening for infants, the elderly, and individuals with pre-existing health conditions. The Vivalytic test offers a rapid and precise diagnosis, providing results in under an hour. This is significantly faster than PCR testing in a central laboratory, which can take up to one day, and culture detection, which can take up to seven days.
The Vivalytic Bordetella test is also an important tool for identifying and treating pertussis in adolescents and adults, as the infection may not always present with the characteristic coughing fits. With the rising number of pertussis cases in Germany and other countries, rapid testing is crucial for controlling the spread of the disease.
The Vivalytic Analyser, which is used for the Vivalytic Bordetella test, is user-friendly and requires only a brief training session for medical staff. The collected sample is placed into a test cartridge, which already contains all necessary reagents. The cartridge is then inserted into the Vivalytic Analyser for automatic processing. The test result is displayed on the screen.
Bosch Healthcare Solutions has obtained CE certification for the Vivalytic Bordetella test, and it is now available for distribution. This is a press release for journalists and does not replace a consultation or recommendation by a medical practitioner.
For press inquiries, please contact Thomas Berroth, Marketing & Communication at Thomas.berroth2@de.bosch.com or +49 (0) 160 90437856.
Bosch Healthcare Solutions GmbH is a wholly owned subsidiary of Robert Bosch GmbH and was established in 2015 to develop products and services that improve people’s health and quality of life. The company employs nearly 300 associates and is headquartered in Waiblingen, Germany.
The Bosch Group is a leading global supplier of technology and services, with over 429,000 associates worldwide (as of December 31, 2023). The company generated sales of 91.6 billion euros in 2023 and operates in four business sectors: Mobility, Industrial Technology, Consumer Goods, and Energy and Building Technology.
With its innovative solutions, Bosch aims to shape universal trends such as automation, electrification, digitalization, connectivity, and sustainability. The company’s expertise in sensors, software, and services allows it to offer customers cross-domain solutions from a single source.
The majority of Bosch’s voting rights are held by Robert Bosch Industrietreuhand KG, which is responsible for safeguarding the company’s long-term independence and financial stability. Additional information is available online at www.bosch.com and www.bosch-press.com.
